Review on Paracetamol Use During Pregnancy
A comprehensive review of paracetamol use by expectant mothers indicates no solid connection between the common pain relief medication and the likelihood of children developing autism or ADHD.
This study was expedited to give mothers-to-be and their healthcare providers trustworthy information following claims from the Trump administration that suggested paracetamol, also known as acetaminophen or Tylenol, might be contributing to growing autism rates.
Diving into this topic, the US president urged women to discuss with their doctors about possibly limiting the use of this medication while pregnant, using emphatic language such as telling them to “fight like hell” against taking it.
Despite the rising autism rates observed over recent years, many experts argue that this increase is largely due to improved awareness, better diagnostic practices, and a broadening of the criteria used to define the condition.
A recent umbrella review in the British Medical Journal looked at existing scientific studies about whether paracetamol use during pregnancy could lead to higher rates of autism or ADHD in children.
The researchers found that the quality of past reviews was generally low, and any perceived links between paracetamol and autism seemed to be largely influenced by genetic factors within families and other variables.
Professor Shakila Thangaratinam, a consultant obstetrician and the senior author of the review from the University of Liverpool, stated that the evidence doesn’t strongly support a link between paracetamol and these developmental disorders. She recommended that if pregnant women need paracetamol for pain or fever, they should feel safe doing so, especially since high fever in pregnancy can pose risks to the unborn child. Notably, alternatives like ibuprofen are not recommended during pregnancy.
The researchers analyzed nine systematic reviews and 40 observational studies regarding paracetamol’s use in pregnancy and its effects on autism, ADHD, and other neurodevelopmental conditions. While all reviews noted at least a potential link, seven of them advised caution in interpreting the results due to not ruling out other influencing factors.
Out of these studies, only one took into account both family genetics and other shared factors such as a mother’s pre-existing health conditions. That particular study, published last year, suggested higher rates of autism and ADHD in 2.4 million Swedish children whose mothers used paracetamol during pregnancy; however, this effect disappeared when comparing siblings exposed to the medication with those who were not, hinting at the idea that maternal genetics or other environmental factors may be at play rather than the medication itself.
Thangaratinam remarked that if there’s a family history of autism or ADHD, it is more likely that such a diagnosis in a child stems from that genetic background rather than any medication taken during pregnancy.
These findings are intended to reassure mothers who may feel guilt about taking paracetamol while pregnant, especially those whose children develop autism or ADHD. Thangaratinam emphasized that current evidence does not indicate that taking paracetamol during pregnancy causes these disorders.
Professor Dimitrios Siassakos, an honorary consultant in obstetrics at University College London, echoed the review’s reinforcement of what global experts have suggested since the comments made by Trump. He underscored that paracetamol is considered the safest option for pain relief during pregnancy and has been widely used for decades without any known adverse effects on autism or ADHD. He added that managing a maternal fever with paracetamol is crucial, as untreated high temperatures could lead to poor pregnancy outcomes, including negative effects on the fetus.
